Allan Pantuck

Director of Translational Research, UCLA Kidney Cancer Program · UCLA David Geffen School of Medicine/UCLA Medical Center

Credentials: · · · · ·

History

Abiraterone in metastatic prostate cancer without previous chemotherapy
New England Journal of Medicine · 2013 · 2,325 citations
The changing natural history of renal cell carcinoma
Review · The Journal of Urology · 2001 · First of 3 authors · 648 citations
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
New England Journal of Medicine · 2016 · 603 citations

Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $475.4K · University of California Los Angeles
2009–2013
UCLA SPORE in Prostate Cancer
National Cancer Institute · P50
Project lead · $1M · University of California Los Angeles
2002–2013
Genetic and Molecular Characterization of Kidney Cancer
National Cancer Institute · K23
Contact PI · $508.7K · University of California Los Angeles
2002–2006

Focal Laser Ablation of Prostate Cancer
Principal investigator · Completed · Early phase 1
Jonsson Comprehensive Cancer Center
2020–2026
Open-Label Extension Study of MCS-2 in the Treatment of Lower Urinary Tract Symptoms (MCS-2-US-c)
Principal investigator · Completed · Phase 3
Health Ever Bio-Tech Co., Ltd.
2011–2014
MCS in the Treatment of Lower Urinary Tract Symptoms
Principal investigator · Completed · Phase 2, Phase 3
Health Ever Bio-Tech Co., Ltd.
2010–2014
A Study Of the Effectiveness Of Pomegranate Pills in Men With Prostate Cancer Before Prostatectomy
Principal investigator · Completed
Jonsson Comprehensive Cancer Center
2009–2012